Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study

Andrew Yiu; Mieke Van Hemelrijck; Hans Garmo; Lars Holmberg; Håkan Malmström; Mats Lambe; Niklas Hammar; Göran Walldius; Ingmar Jungner; Wahyu Wulaningsih

doi:10.18632/oncotarget.16198

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study

Andrew Yiu, Mieke Van Hemelrijck, Hans Garmo, Lars Holmberg, Håkan Malmström, Mats Lambe, Niklas Hammar, Göran Walldius, Ingmar Jungner and Wahyu Wulaningsih _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:42332-42342. https://doi.org/10.18632/oncotarget.16198

Metrics: PDF 1958 views | HTML 2688 views | ?

Abstract

Andrew Yiu1, Mieke Van Hemelrijck1,4, Hans Garmo1,2, Lars Holmberg1,2,3, Håkan Malmström4, Mats Lambe3,5, Niklas Hammar4,6, Göran Walldius7, Ingmar Jungner8 and Wahyu Wulaningsih1

1King’s College London, Division of Cancer Studies, Cancer Epidemiology Group, London, UK

2Regional Cancer Centre, Uppsala, Sweden

3Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden

4Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

5Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

6AstraZeneca R&D, Mölndal, Sweden

7Unit of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

8Department of Medicine, Clinical Epidemiological Unit, Karolinska Institutet and CALAB Research, Stockholm, Sweden

Correspondence to:

Wahyu Wulaningsih, email: [email protected]

Keywords: uric acid, cancer, prospective study

Received: November 01, 2016 Accepted: February 06, 2017 Published: March 15, 2017

ABSTRACT

Objectives: Serum uric acid has been suggested to be associated with cancer risk. We aimed to study the association between serum uric acid and cancer incidence in a large Swedish cohort.

Results: A positive association was found between uric acid levels and overall cancer risk, and results were similar with adjustment for glucose, triglycerides and BMI. Hazard ratio (HR) for overall cancer for the 4^th quartile of uric acid compared to the 1^st was 1.08 (95% CI: 1.05–1.11) in men and 1.12 (1.09 – 1.16) in women. Site-specific analysis showed a positive association between uric acid and risk of colorectal, hepatobiliary, kidney, non-melanoma skin, and other cancers in men and of head and neck and other cancers in women. An inverse association was observed for pulmonary and central nervous system (CNS) cancers in men and breast, lymphatic and haematological, and CNS malignancies in women.

Materials and Methods: We included 493,281 persons aged 20 years and older who had a measurement of serum uric acid and were cancer-free at baseline in the AMORIS study. Multivariable Cox proportional hazards regression was used to investigate sex-specific quartiles of serum uric acid in relation to cancer risk in men and women. Analysis was further adjusted for serum glucose, triglycerides and, where available, BMI. Site-specific analysis was performed for major cancers.

Conclusions: Altered uric acid levels were associated with risk of overall and some specific cancers, further indicating the potential role of uric acid metabolism in carcinogenesis.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16198

Publication Alerts

Research Papers:

Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study

Abstract